Trygg Pharma acquires Epax from Austevoll Seafood

Trygg Pharma AS - a company that will be jointly owned by Aker BioMarine ASA and
an affiliate of Lindsay Goldberg LLC through a newly established joint venture
company (cf. the separate notice of today) - has entered into an agreement to
acquire 100% of the shares in Epax Holding AS (together with its subsidiaries
"Epax"), a wholly owned subsidiary of Austevoll Seafood ASA. Epax is the world's
premier high concentrate omega-3 supplement manufacturer. Epax employs a total
of 74 people.

Please see attached.

For further information regarding Trygg Pharma and Epax, please contact:
Egil Bodd, Chairman of the board, Trygg Pharma, tel.: +47 900 20 341
Aaron Kramer, CEO, Trygg Pharma, tel.: +47 916 30 130

For further information regarding Aker BioMarine, please contact:
Fredrik Nygaard, CFO and IR contact, Aker BioMarine, tel.: +47 24 13 00 00


This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)


[HUG#1442506]